Try a new search

Format these results:

Searched for:

active:yes

exclude-minors:true

Department/Unit:Medicine

Total Results:

17591


Optimizing Team Integration of Critical Care Pharmacists: Where We Go Next

Smith, Susan E; Henry, Kelli; Papadopoulos, John; Sikora, Andrea; Bektas, Aeryana N; Heavner, Mojdeh S
Critical care pharmacists (CCPs) are essential members of the intensive care unit team who provide comprehensive medication management to improve patient outcomes, safety, and cost efficiency. This article highlights barriers to optimal integration of CCPs within multidisciplinary teams as well as opportunities to address them. Persistent barriers include financial, workforce, data, interprofessional, and regulatory. Strategies to address these gaps may involve standardized metrics, innovative staffing models, and research to strengthen evidence-based implementation. Metrics should include all members of the Stakeholder Triad and should include a mix of workload metrics, safety and efficacy metrics, and work-design metrics.
PMID: 43003541
ISSN: 1557-8232
CID: 6075759

Percutaneous Coronary Intervention for Heart Failure due to Coronary Artery Disease

Singh, Arushi; Zhang, Robert S; Bangalore, Sripal
The role of revascularization and percutaneous coronary intervention (PCI) in patients with acute coronary syndrome is well established. However, the incremental value of revascularization over guideline-directed medical therapy is controversial. Currently available data supports the use of PCI to improve angina and quality of life for chronic coronary disease and heart failure (HF). However, there is insufficient data to support revascularization with PCI to improve mortality, reduce cardiovascular events, or improve ejection fraction over medical therapy alone. Additional trials are necessary to identify HF patients who may benefit from revascularization, and the optimal revascularization strategy for this population.
PMID: 43003527
ISSN: 2211-7466
CID: 6075753

Optimizing Team Integration of Critical Care Pharmacists: A History of Critical Care Pharmacy Practice and Evolving Definition of "Optimal Practice"

Smith, Susan E; Bektas, Aeryana N; Henry, Kelli; Heavner, Mojdeh S; Papadopoulos, John; Sikora, Andrea
Critical Care Pharmacists (CCPs) are essential members of the intensive care unit (ICU) team who provide comprehensive medication management to improve patient outcomes, safety, and cost efficiency. This article highlights best practices for optimal CCP integration, including optimal patient-to-pharmacist ratios, participation in interprofessional rounds, team-based practice models, and expanded coverage across all shifts. The Triple Domain framework is useful to evaluate CCP value across patients, health care teams, and institutions. Best practices include an ICU patient-to-CCP ratio of less than or equal to 15:1 and inclusion of CCPs on daily interprofessional rounds.
PMID: 43003540
ISSN: 1557-8232
CID: 6075756

Heterogeneity in proteomic risk factors for coronary heart disease by sex and menopause status

Herold, Janina M; Surapaneni, Aditya; Coresh, Josef; Mavromatis, Lucas; Ruggles, Kelly V; Boerwinkle, Eric; Reynolds, Harmony; Ballantyne, Christie M; Yu, Bing; Flaherty, Carina; Grams, Morgan E
BACKGROUND/UNASSIGNED:Coronary heart disease (CHD) is the leading cause of morbidity and mortality worldwide, yet current prediction tools do not fully capture sex differences in risk. Menopause further modifies women's risk of CHD, but underlying molecular mechanisms are not well understood. Proteomic profiling may provide new insights into these mechanisms. METHODS/UNASSIGNED:We analyzed 4,877 SomaScan™-based plasma proteins in 10,034 Atherosclerosis Risk in Communities (ARIC) participants. Using linear regression, we identified sex- and menopause-related differences in circulating protein concentrations. We performed pathway enrichment analyses to capture underlying biological mechanisms. To evaluate the associations between proteins and incident CHD and differences by sex or menopause status, we applied Cox regression. Finally, we used LASSO regression to identify proteins that improve CHD risk prediction beyond an established clinical model. RESULTS/UNASSIGNED:We observed significant differences in circulating proteins by sex and menopausal status, including early changes during the menopausal transition. We found protein associations with incident CHD differed markedly by sex and menopausal stage: eight proteins were associated with CHD in men, compared with 54 in women, and six and 17 proteins in peri‑ and postmenopausal women, respectively. In risk prediction analyses, adding sex-specific protein panels improved CHD prediction (ΔC-statistic=0.05 in men and 0.03 in women), with similar improvement across menopausal stages. CONCLUSIONS/UNASSIGNED:Proteomic profiles underlying CHD risk differ substantially by sex and menopausal stage. These findings suggest potential biological heterogeneity in CHD and support the study of sex- and menopause-related differences in underlying mechanisms.
PMCID:13676126
PMID: 42893041
ISSN: 2666-6677
CID: 6074846

NP-101 in combination with nivolumab and ipilimumab in metastatic extrapulmonary neuroendocrine carcinomas (EP-NECs): A pilot study

Mohamed, A; Azmi, A; Kocak, M; Sonbol, M B; Konda, B; Dowlati, A; Nagel, C; Haider, M; Laderian, B; Asa, S L; Tirumani, S H; Garcia, J; Mahipal, A; Bajor, D; Chakrabarti, S; Selfridge, J E; Conces, M; Lumish, M; Hoehn, R S; Winter, J; Fu, P; Ammori, J; Hardacre, J; Henke, L E; Khan, H Y; Morgan, C; Raheem, D Abedal; Donohue, D; Fowler, P; Kaseb, A
Extrapulmonary neuroendocrine carcinomas (EP-NECs) are a heterogeneous group of rare tumors with poor clinical outcomes. These patients have limited treatment options after progressing on first-line platinum-based chemotherapy. Although dual immune checkpoint inhibitors (ICIs) with anti-CTLA-4 and anti-PD-1 blockade have significantly improved outcomes for several solid tumors, they demonstrated modest activity for EP-NECs with 9-26% response rates and low survival rates. Preliminary data demonstrated that NP-101 (Nigella sativa formulation) enhances T-cell infiltration and is synergistic with dual ICPIs in NECs' cellular models. This pilot study evaluated the tolerability and efficacy of NP-101 plus nivolumab and ipilimumab in patients with metastatic EP-NECs refractory to first-line platinum-based chemotherapy. This is a single-arm pilot study (NCTNCT05262556) in which patients with metastatic EP-NECs received NP-101 (oral capsules), 3,000 mg daily, plus ICPIs (intravenous nivolumab 3 mg/kg and ipilimumab 1 mg/kg) every 3 weeks for four cycles. Nonprogressors received NP-101 (3,000 mg daily), plus biweekly maintenance of nivolumab (240 mg), and then completed 24 weeks of treatment. Treatment-related adverse events (TR-AEs) were characterized according to CTCAE v4.03. The response rate was estimated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. The Kaplan-Meir method was used to estimate median PFS and OS. Twelve patients received ≥1 dose of NP-101 and nivolumab plus ipilimumab. There were no dose-limiting toxicities (DLTs). Grade 1/2 TR-AEs occurred in 100% (12/12) of patients. The most common G1/2 TR-AEs included the following: fatigue (75%), nausea (41.7%), pruritus (41.7%), muscle weakness (33.3%), vomiting (25%), rash (25%), and abdominal pain (25%). Eight patients (66%) experienced grade 3/4 TR-AEs, including rash (33.3%), nausea (16.7%), vomiting (16.7%), and transaminitis (16.7%). No treatment-related grade 5 toxicities or deaths were recorded. The objective response rate was 41.7% (2/12 (16%) complete response (CR) + 3/12 (25%) partial response (PR); 95% CI: 15.2-72.3%) for all patients and 50% (2/8 CR + 2/8 PR, 95% CI: 0.16-0.84) for patients with NEC of gastrointestinal origin. The median duration of response was 7.5 months. As for the median progression-free survival, it was 5.7 months, and the median overall survival (OS) was 10.5 months with a median follow-up of 10.4 months. The combination of NP-101 plus dual ICPIs (nivolumab and ipilimumab) was safe and well tolerated with preliminary evidence of antineoplastic activity. Currently, a randomized phase II clinical trial evaluating the combination is under development.
PMID: 42012995
ISSN: 1479-6821
CID: 6076226

Gene regulatory network analysis identifies auranofin as an anti-atherosclerotic drug

Amadori, Letizia; Calcagno, Claudia; Kaur, Ravneet; Horstmann, Hauke; He, Tianshe; Gildea, Michael; Sakurai, Ken; Chong, Peik Sean; Shamailova, Roza; Naidu, Sonum; Hill, Christopher A; Sajja, Swathy; Bresciani, Jordan; La Forest, Maxwell; Ghotbi, Adam A; Soler, Raphael; Faries, Christopher; Fisher, Edward A; Fayad, Zahi A; Fillmore, Nathanael R; Ramos-Cejudo, Jaime; Readhead, Benjamin; Dudley, Joel T; Bjorkegren, Johan L M; Giannarelli, Chiara
Gene-regulatory networks (GRNs) offer a mechanistic framework for dissecting the complex molecular and genetic architecture of coronary artery disease and for identifying new therapeutic opportunities. Here, we present a GRN-driven drug-repurposing strategy that integrates transcriptional signatures induced by silencing key drivers of the human arterial wall foam cell regulator GRN 42 with drug-induced gene expression profiles from the NIH LINCS program. In vitro screening of top candidate compounds validates the computational predictions, identifying candidate foam cell modulators and showing that auranofin, an FDA-approved gold salt used to treat rheumatoid arthritis, effectively reduces foam cell formation. In vivo, auranofin attenuates atherosclerosis and inflammation in both male mice and rabbits. Clinically, auranofin was associated with reduced cardiovascular risk in a retrospective cohort of patients with rheumatoid arthritis. Together, these findings show that a GRN-based drug-repurposing framework, coupled with preclinical and clinical validation, can uncover new therapeutic applications for existing drugs, including auranofin, in coronary artery disease.
PMCID:13631248
PMID: 42823455
ISSN: 2041-1723
CID: 6076237

Necrotizing soft-tissue infections survival guide in adult patients: A position statement by the Global Alliance for Infections in Surgery

Sartelli, Massimo; Coccolini, Federico; Labricciosa, Francesco M; Al-Hasan, Majdi N; Buonomo, Luis; Cheadle, William G; De Simone, Belinda; Duane, Therese M; Hardcastle, Timothy C; Hecker, Andreas; Kirkpatrick, Andrew W; Leone, Marc; Martin-Loeches, Ignacio; Marwah, Sanjay; Maves, Ryan C; Montravers, Philippe; Podda, Mauro; Rello, Jordi; Tattevin, Pierre; Tessier, Jeffrey; Tranà, Cristian; Ulrych, Jan; Vallicelli, Carlo; Vigutto, Gabriele; Watkins, Richard R; Coimbra, Raul; Catena, Fausto
Necrotizing soft-tissue infections (NSTIs) are acute, rapidly progressive infections of soft tissues, often associated with signs of severe systemic toxicity and progressive multi-organ failure. This rapid, often fatal progression of local disease mandates timely diagnosis. Delays in diagnosis and treatment may have dire consequences. Effective treatment includes appropriate debridement associated with directed antibiotic therapy and hemodynamic support. Early surgical debridement with complete removal of necrotic tissue, including potential amputation, is essential to decrease mortality and other complications. The initial treatment of patients with NSTIs requires collaboration between surgeons, intensivists, and infectious disease specialists. Extensive tissue debridements may create challenges for wound care, preservation of function, reconstruction, and cosmesis, requiring ongoing multidisciplinary collaboration. This evidence-based position statement has been signed by a representative multidisciplinary working group of experts, with its main objective being to describe best practices for the first-line management of NSTIs in adult patients.
PMID: 41417687
ISSN: 2163-0763
CID: 6076067

Assessing the relationship between body mass index and influenza-like illness risk and symptom severity among military health system beneficiaries vaccinated against influenza: a pooled prospective cohort study from a randomized trial

Gu, Mofan; Richard, Stephanie A; Colombo, Rhonda E; Schmidt, Kat; Ganesan, Anuradha; Campbell, Wesley R; Mende, Katrin; Seshadri, Srihari; Saperstein, Adam; Hrncir, David E; Maves, Ryan C; O'Connell, Robert J; Spooner, Christina E; Simons, Mark P; Housel, Laurie A; Williams, Alan; Powers, John H; Fries, Anthony; Coles, Christian L; Burgess, Timothy H; Pollett, Simon D
INTRODUCTION/UNASSIGNED:Obesity prevalence is rising globally and associated with increased influenza mortality. The relationship between obesity and influenza-like-illness (ILI) incidence and symptom severity is less clear. MATERIALS AND METHODS/UNASSIGNED:US Military Health System (MHS) beneficiaries enrolled in a randomized influenza vaccine trial received one of three influenza vaccines and were followed for ILI via weekly surveys throughout one influenza season. Participants were pooled across vaccine arms into a prospective cohort. We compared ILI risk and ILI symptom severity (Flu-PRO) across body mass index (BMI) categories using multivariable regression models. RESULTS/UNASSIGNED:Among the 8,334 participants with >50% response rates to weekly ILI surveys, 42% had an overweight-range BMI and 24% had an obesity-range BMI. The median age was 36.2, and 86% had no baseline comorbidities. Over one quarter of the participants (27%) reported at least one ILI during follow-up, with a median duration of 11 days. Participants with an overweight and obesity-range BMI were more likely to report ILIs [adjusted incidence rate ratio (aIRR) 1.18 (95% confidence interval (CI): 1.05-1.33) and 1.59 (95% CI: 1.37-1.84), respectively]. Participants with obesity also had higher risks of reporting moderate-to-severe symptoms in four Flu-PRO domains: gastrointestinal, respiratory, systemic, and throat [adjusted risk ratio (aRR) of 1.64 (95% CI: 1.01-2.70), 1.33 (95% CI: 1.05-1.67), 1.32 (95% CI: 1.06-1.63), and 1.20 (95% CI 1.02-1.40) respectively]. CONCLUSIONS/UNASSIGNED:Higher BMI was associated with ILI incidence and severity. These findings prompt further research into optimal strategies to reduce the impact of ILI in MHS settings and the general population.
PMCID:13422495
PMID: 42534960
ISSN: 2296-2565
CID: 6076074

The Frame of Survival for Sepsis: A Practical Systems Framework for Time-Sensitive Critical Illness in Low-Resource Settings

Hidalgo, Jorge L; Akech, Samuel O; Acharya, Subhash P; Coopersmith, Craig M; Jacob, Shevin T; Johnston, Cintia; Kissoon, Niranjan; Machado, Flávia R; Maves, Ryan C; Molyneux, Elizabeth; Morrow, Brenda M; Myatra, Sheila N; Pérez Cornejo, M Susana; Perez-Fernandez, Javier; Permpikul, Chairat; Piyavechviratana, Kunchit; Rhodes, Andrew; Kortz, Teresa B; Kumar, Vishakha K; Ulisubisya, Mpoki M; Nadkarni, Vinay
OBJECTIVES:Sepsis is a time-sensitive cause of preventable death worldwide, with disproportionate mortality in low-resource settings (LRS). Many recommendations in international sepsis guidance presume resources unavailable in many facilities and communities. We sought to develop a practical framework that helps health systems embed feasible sepsis actions within broader emergency and essential critical care systems, while highlighting where evidence is limited and where local learning systems are needed. DATA SOURCES:A targeted scoping review of peer-reviewed and grey literature on sepsis epidemiology, emergency care systems, essential emergency and critical care, implementation strategies, and quality improvement (QI) in LRS; and key guideline and policy documents relevant to sepsis and emergency care. STUDY SELECTION:We prioritized publications and guidance relevant to LRS, including observational studies, pragmatic implementation reports, consensus statements, and policies addressing emergency care organization, workforce, supply chains, diagnostics, and QI. DATA EXTRACTION:Task force members abstracted actionable strategies, implementation barriers/enablers, and feasibility considerations across the care continuum (community, transport/prehospital, facility-based acute care, and referral). We also identified domains where guideline certainty is low or indirect for LRS. DATA SYNTHESIS:A Society of Critical Care Medicine-convened multidisciplinary task force iteratively developed the "Sepsis Frame of Survival" using a structured process that included 1) scoping evidence review, 2) a Delphi-style prioritization of candidate framework elements by importance and feasibility, and 3) a structured consensus meeting ("Utstein-style" conference format) to finalize the model and its priority actions. We produced a concise implementation roadmap and a feasible measurement set aligned with resource constraints. CONCLUSIONS:The Sepsis Frame of Survival is a pragmatic model to organize sepsis improvement as part of emergency and essential critical care strengthening. It emphasizes high-impact actions that can be implemented with limited resources (triage and early recognition, timely antimicrobials, oxygen and basic supportive care, cautious fluid resuscitation with reassessment, source control and referral, diagnostics/microbiology where feasible, and QI). The framework explicitly distinguishes near-term, feasible changes from longer-term system investments and highlights the need for locally generated evidence to guide quality indicators and resuscitation strategies in LRS.
PMID: 41860329
ISSN: 1530-0293
CID: 6076072

Influenza-like illness in cigarette smokers and electronic-cigarette users: a secondary analysis from the PAIVED study

Jones, Rachael D C; Schmidt, Kat; Schofield, Christina; Ganesan, Anuradha; Campbell, Wesley; Hrncir, David; Lalani, Tahaniyat; Mende, Katrin; Markelz, Ana E; Berjohn, Catherine M; Housel, Laurie; Tilley, Drake H; Saperstein, Adam; Williams, Alan; McClenathan, Bruce; Collins, Limone; Spooner, Christina; Seshadri, Srihari; Maves, Ryan C; O'Connell, Robert J; Pollett, Simon; Simons, Mark P; Powers, John H; Coles, Christian L; Colombo, Rhonda E; Burgess, Timothy H; Richard, Stephanie A
BACKGROUND/UNASSIGNED:The Pragmatic Assessment of Influenza Vaccine Effectiveness in the Department of Defense (PAIVED) study was a clinical trial of three influenza vaccines in military beneficiaries enrolled at 10 military treatment facilities over four influenza seasons (2018/19-2021/22). This secondary analysis aimed to assess the relationship between cigarette smoking and e-cigarette use and influenza-like illness (ILI) incidence and severity. METHODS/UNASSIGNED:Demographic information, including cigarette smoking and e-cigarette use, was collected at enrollment. ILIs were identified during the influenza season of enrollment using weekly surveys. ILI symptoms were reported using the inFLUenza Patient-Reported Outcome (FLU-PRO) instrument. The relationship between smoking status and risk of reporting an ILI was estimated using Poisson regression; ILI severity was compared by cigarette smoking and e-cigarette use using multivariable linear regression. RESULTS/UNASSIGNED:Among 8,708 participants with cigarette smoking status, 4.3% were current smokers and 11.9% were former smokers. Current cigarette smokers reported higher respiratory domain scores (0.24 (95% CI: 0.07, 0.41)) than non-smokers; former cigarette smokers were at higher risk of reporting an ILI than non-smokers [rate ratio 1.11 (95% CI: 1.02, 1.20)] and reported ILI episodes that were on average 1.23 days longer in duration (95% CI: 0.29, 2.17). Among 8,119 participants with e-cigarette use status, 3.9% were current users and 2.6% were former users. Current e-cigarette users reported more than one additional day with limited activity (1.14 days, 95% CI: 0.10, 2.18) and 0.78 additional days with fever (95% CI, 0.20, 1.35); former e-cigarette users were at higher risk of reporting an ILI than nonusers [rate ratio 1.20 (95% CI, 1.04, 1.38)] and reported higher respiratory domain scores than non-users (0.27 (95% CI 0.08, 0.46)). CONCLUSION/UNASSIGNED:We observed slightly higher ILI risk in former cigarette smokers and e-cigarette users, longer symptom duration in former cigarette smokers, and higher respiratory symptom scores in current cigarette smokers and former e-cigarette users compared to non-smokers/users. Findings in this secondary analysis are exploratory and hypothesis-generating; additional studies are needed to confirm the relationships reported here.
PMCID:13130645
PMID: 42077984
ISSN: 2296-2565
CID: 6076073